Rankings
▼
Calendar
ALT FY 2024 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena
ALT
Altimmune, Inc.
$353M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$20,000
-95.3% YoY
Gross Profit
$20,000
100.0% margin
Operating Income
-$103M
-515860.0% margin
Net Income
-$95M
-475295.0% margin
EPS (Diluted)
$-1.34
Cash Flow
Operating Cash Flow
-$80M
Free Cash Flow
-$80M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$139M
Total Liabilities
$16M
Stockholders' Equity
$124M
Cash & Equivalents
$37M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$20,000
$426,000
-95.3%
Gross Profit
$20,000
$426,000
-95.3%
Operating Income
-$103M
-$96M
-7.6%
Net Income
-$95M
-$88M
-7.5%
← Q4 2023
All Quarters
Q1 2024 →